Page 273 - Read Online

Lecchini et al. HCC vascular invasion in sorafenib treatment

A B

P < 0.05

No macrovascular invasion
Macrovascular invasion

C D

P < 0.0001 P < 0.05

E F

P < 0.005
P < 0.05

Dose reduction
Full dose

Figure 1: Overall survival (OS) of the whole patient population and survival according to risk factors. (A) Median OS for sorafenib treated
patients was 8.5 months; (B) presence of macroscopic neoplastic vascular invasion of the portal venous system, present in 56% of
subjects, was a strong negative predictor on survival, with a median OS of 5.5 vs. 12 months observed in patients without neoplastic
thrombosis; (C) a duration of sorafenib treatment beyond median time of 2.5 months positively influenced outcome (median OS 11 vs.
3.5 months); (D) analysis of radiological response rate at 8 weeks of treatment showed a significant impact on survival: median OS was
12.5 months in subjects with stable disease or partial response and 9.5 months in progressive disease patients; (E) dose reduction showed
a benefit on survival (median OS 11 vs. 5 months); (F) sorafenib daily dose below median (800 mg) was associated with better survival
(median OS 10.5 vs. 6 months)

similarly to what previously reported [28,29] (HR = 1.7), survival. Indeed, this condition severely impacts on
thus confirming that the presence of portal neoplastic the natural history of the disease, characterized by an
thrombosis is a very negative prognostic factor on aggressive disease course, because of fast spread
Hepatoma Research ¦ Volume 3 ¦ November 16, 2017 265